Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tadalafil + dapoxetine is a fixed-dose combination of two small molecule drugs used primarily in men for the treatment of erectile dysfunction (ED) and premature ejaculation (PE). Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor that works by increasing blood flow to the penis, facilitating erection during sexual stimulation. Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in nerves, improving control over ejaculation and prolonging intravaginal ejaculatory latency time. The combination addresses both ED and PE simultaneously, offering dual benefits for men experiencing both conditions[2][4][5][8][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tadalafil + dapoxetine.